Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study’s initial hypothesis, and therefore the alliance made the decision to terminate the trial in alignment with the independent Data Monitoring Committee. The alliance between Merck KGaA,…
Pfizer Drug Okayed for Patients Suffering From Acute Myeloid Leukemia
Pfizer and Novartis Enter Clinical Development Agreement to Advance the Treatment of NASH
Pfizer has entered into a non-exclusive clinical development agreement with Novartis to investigate one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH). The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol O Acyltransferase…
In Preparation for New CEO, Pfizer Changes Up Executive Team
Pfizer Inc. announced its executive team that will report to Albert Bourla, incoming CEO, coincident with the commencement of his new role effective January 1, 2019. “We are at a pivotal moment in Pfizer’s history, with Ian Read having positioned the company with a strong portfolio of marketed products, a deep pipeline and the clear potential…
Pfizer And Allogene Therapeutics Enter Into Asset Contribution Agreement
Pfizer Inc. nd Allogene Therapeutics, Inc. announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer. Allogene, co-founded and led by former executives of Kite Pharma, is positioned…
Pfizer NDA For Lung Cancer Treatment Granted U.S. Priority Review
U.S., EU, and Japan health authorities accept regulatory submissions for review of Pfizer’s third-generation ALK inhibitor lorlatinib. The U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to Pfizer Inc.’s New Drug Application for lorlatinib, an investigational, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of patients with ALK-positive metastatic non-small…
Pfizer Signs License Agreement to Sell Fungal Infection Drug in Europe
Pfizer Receives EU Approval for Besponsa Leukemia Treatment
Pfizer’s Xeljanz Authorized for Marketing in the European Union
Xeljanz (tofacitinib citrate) receives marketing authorization in the European Union for the treatment of moderate to severe active rheumatoid arthritis (RA). Pfizer Inc. announced today that the European Commission (EC) has approved Xeljanz (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active…
